Roche sees profit growth hiccup as old drug guard gets replaced
Bloomberg Roche Holding AG expects to dodge the worst of the fallout from the expiry of patents on its blockbuster medicines. The Swiss drugmaker is rolling out new treatments such as the cancer immune therapy Tecentriq and wrapping up costly clinical trials for two experimental medicines to soften the blow from competition to its ageing cancer blockbusters. That means ...
Read More »